Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) insider John A. Lewicki sold 7,416 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $3.69, for a total transaction of $27,365.04. Following the completion of the sale, the insider now directly owns 65,587 shares of the company’s stock, valued at $242,016.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Mereo BioPharma Group Trading Down 0.3 %
Shares of Mereo BioPharma Group stock opened at $3.48 on Friday. Mereo BioPharma Group plc has a 12-month low of $1.07 and a 12-month high of $4.50. The company has a 50-day simple moving average of $3.29 and a 200 day simple moving average of $3.18.
Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) last announced its earnings results on Wednesday, May 15th. The company reported ($0.01) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the stock. SVB Leerink increased their price objective on shares of Mereo BioPharma Group from $6.00 to $8.00 and gave the company an “outperform” rating in a research note on Thursday, June 20th. Baird R W upgraded shares of Mereo BioPharma Group to a “strong-buy” rating in a research note on Thursday, June 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a research report on Wednesday, June 12th. Robert W. Baird started coverage on shares of Mereo BioPharma Group in a research report on Thursday, June 13th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Needham & Company LLC increased their target price on shares of Mereo BioPharma Group from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, June 12th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Mereo BioPharma Group has a consensus rating of “Buy” and an average price target of $7.50.
View Our Latest Stock Analysis on MREO
About Mereo BioPharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Recommended Stories
- Five stocks we like better than Mereo BioPharma Group
- CD Calculator: Certificate of Deposit Calculator
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- What are earnings reports?
- MongoDB Stock: Analysts Recommend Buying the Dip
- Financial Services Stocks Investing
- UniFirst Stock: Value-Building Sends a Signal to the Market
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.